leadf
logo-loader
OTCQB:MMEDF

MindMed

Receive alerts
Market:
OTCQB
Market Cap:
$451.92 m
Price
1.60 USD
Change
-3.36%
52 weeks high
1.98
52 weeks low
0.08

JR Rahn

Co-Founder, Director & Co-CEO

JR is a former Silicon Valley tech executive who realized that transformational solutions to mental illness and addiction might lie in psychedelic medicines. He spent 2 years researching and began personally investing in psychedelic research through his investment company. JR partnered with drug development veteran Stephen Hurst to start Mindmed in 2019, assembling a leading clinical drug discovery and development team with vast experience conducting clinical trials and research on drug candidates derived from psychedelics. Before starting Mindmed, JR worked in market expansion and operations at Uber. After leaving Uber, he was backed by the Silicon Valley tech accelerator Y Combinator for his company Upgraded. Upgraded is partnered with Apple to provide device financing for Apple customers in Europe.

Stephen L. Hurst, JD

Co-Founder, Executive Chair & Co-CEO

Steve has more than thirty-five years’ experience in the biopharmaceutical industry including work for The Immune Tolerance Institute, The Regents of the University of California, The World Bank and BIO Ventures for Global Health. In addition, Steve has previously advised on psychedelic therapies research and clinical trial designs.

He has held senior executive positions with Sequential, Inc. and Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.), where he helped the company grow to over 700 employees and raised more than $700 million in investment capital. Steve and Drs. Freeman and Glick co-founded Savant HWP, Inc., in 2009 to advance 18-MC to clinical trials. He is a graduate of Golden Gate University, School of Law and the University of California, Berkeley.

Scott Freeman, MD

Co-Founder, President & Chief Medical Officer

Scott has extensive experience in clinical trial work and FDA regulatory strategy. As the CMO of Savant he was the primary investigator behind the National Institutes of Health (NIH) grant in bringing 18-MC to IND and its first-in-human clinical trial. He served as Vice President of Clinical Development at Onyx Pharmaceutical and was head of both the clinical development and operations groups, which lead to FDA approval of Nexavar for kidney and liver cancer. Dr. Freeman was an Associate Professor at Tulane University and a guest researcher at the NIH in both basic and clinical research. Scott earned his BA from the University of Colorado and received his MD from the University of Nevada.

Carol Nast

Chief Operating Officer

Carol has spent her career in executive level positions with large multinational companies and early stage companies in the medical industry. She is a recognized expert in product development and commercialization and has extensive experience in the management of complex, multinational partner programs and has lead successfully the development and commercialization of over 100 products. Carol was COO at NuGen, a genomics company, and served in executive level positions at Inhale Therapeutics (Nektar), Syva (a division of Syntex Pharmaceuticals,) BioRad and Pfizer. Her passion is the successful launch and adoption of breakthrough products in emerging markets that have significant impact by solving a vexing challenge.

Dave Guebert

Chief Financial Officer

Dave Guebert is a CPA, qualified in both Alberta and Pennsylvania, and a Member of the Institute of Corporate Directors. He started his career in 1979 at Deloitte where he qualified for his CPA designations.  He went on to serve as the Controller for the XV Olympic Winter Games from 1986 to 1988.  Since then has taken on increasing senior roles, acting as Chief Financial Officer for a number of public and private companies, primarily in the technology industry.  He currently sits as a board member and Audit Committee Chair for Legend Power Systems (TSXV: LPS), RMMI Inc. (CSE: RMMI) and Quisitive Technology Solutions, Inc. (TSXV: QUIS). From 2010 to 2017, he was board member and Audit Committee Chair of Merus Labs International Inc. (TSX: MSL; NSDQ: MSLI), a specialty pharmaceutical company.

Dave is a graduate of the University of Saskatchewan.  He has served as a volunteer on the Audit and Finance Committee of the Calgary Stampede and the Board of the Calgary Olympic Development Association as well as various roles in hockey, baseball and his community.

Donald Gehlert, PhD

Chief Scientific Officer

Don has extensive experience in drug discovery and expertise in key functional areas of exploratory development and disease biology.  During his career at Lilly, Don led or participated in teams that introduced 19 molecules into the Lilly pipeline including both small and large molecule therapies. He also participated on Phase I and Phase II clinical development teams that designed and delivered translational proof of concept studies in the areas of ADHD, obesity, AUD, depression, pain and migraine.  He is a co-author on 182 publications and a co-inventor on 15 issued and pending patents.

Jeanne Bonelle

EVP, Technical Operations

Jeanne has over thirty years of experience developing quality organizations within startup firms as well as transitioning to commercial operations. Her last four positions were to establish quality systems within the developmental phase for a wide range of products, including Senior Director of Quality Assurance at Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.); Director of Quality Assurance at Cholestech Inc. (now Alere Inc.); Manager of Quality Assurance at BioTrack, (now a subsidiary of Roche Diagnostics GmbH); Manager of Quality Assurance at BioResponse Inc. (now Baxter Health Care). Ms. Bonelle obtained her degree in Chemistry from California State College, Dominguez Hills, CA.

Nico Forte

Senior Director, Business Operations and Development

Nico has more than twenty-five years of marketing and business development experience primarily in the biopharma and medical device industries. His background includes B2B agency marketing and communication work for Bristol-Myers and Mead Johnson Oncology divisions as well as business development roles for Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.). He directed US operations for the Australian medical device company Signostics, LTD (now EchoNous, Inc.) before joining Konica Minolta Medical Imaging to expand their imaging expertise into handheld ultrasound. Mr. Forte holds a BA degree in Economics from The College of William and Mary in Virginia.

Madeline Feldman

Director of Operations & Administration

Madeline has a background supporting startups through corporate innovation and investor relations, fundraising for venture capital funds and non-profit organizations, and building out operational departments in various industries. She has a love for performing arts and works with artists in creating and producing stage shows for major venues and resorts.

Collin Gage

Head of Corporate Development

Collin began his career at Point72 Asset Management where he was responsible for research within the market intelligence division. From there, he worked at the Genjiko Family Office. While at Genjiko he was responsible for selecting and researching alternative investments, expansionary efforts, and capital management. Genjiko is the family office of a former Fortune 50 C-Level executive. During this period, Collin also helped co-found a venture capital fund called Presight Capital. Presight invests in early stage companies throughout the software, frontier tech & biotech space. Collin received his BA as a dual major in Economics and Finance from The Ohio State University. He is currently pursuing an MA in Data Science from Harvard University.

To get in touch, please click here